Genelux’s (GNLX) “Speculative Buy” Rating Reaffirmed at Benchmark

Benchmark reissued their speculative buy rating on shares of Genelux (NASDAQ:GNLXFree Report) in a report released on Wednesday morning, Benzinga reports. They currently have a $30.00 target price on the stock.

Separately, HC Wainwright lowered their price target on Genelux from $35.00 to $32.00 and set a buy rating for the company in a report on Tuesday.

Check Out Our Latest Stock Report on GNLX

Genelux Price Performance

Genelux stock opened at $4.86 on Wednesday. Genelux has a 52 week low of $4.86 and a 52 week high of $40.98. The stock has a fifty day moving average of $7.50 and a 200-day moving average of $13.19.

Hedge Funds Weigh In On Genelux

A number of institutional investors have recently modified their holdings of GNLX. AE Wealth Management LLC increased its holdings in Genelux by 1,370.0% in the 3rd quarter. AE Wealth Management LLC now owns 194,875 shares of the company’s stock worth $4,772,000 after purchasing an additional 181,618 shares in the last quarter. D.A. Davidson & CO. acquired a new position in Genelux in the 3rd quarter worth about $237,000. Advisor Resource Council acquired a new position in Genelux in the 4th quarter worth about $233,000. Barclays PLC increased its holdings in Genelux by 516.4% in the 3rd quarter. Barclays PLC now owns 3,384 shares of the company’s stock worth $83,000 after purchasing an additional 2,835 shares in the last quarter. Finally, Whittier Trust Co. acquired a new position in Genelux in the 3rd quarter worth about $175,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Company Profile

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

Featured Articles

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.